Background: Vitamin D can be one of the candidate substances that are used as additional supplementation in the treatment of anxiety-related disorders in women with estrogen imbalance.
Materials and methods: The aim of the present study was to examine the effects of chronic cholecalciferol administration (1.0, 2.5 or 5.0 mg/kg/day, s.c.) on the anxiety-like behavior and monoamines levels in the rat hippocampus following ovariectomy in female rats. Cholecalciferol was given to ovariectomized (OVX) rats and OVX rats treated with 17β-estradiol (17β-E2, 0.5 μg/rat, s.c.). The anxiety-like behavior was assessed in the elevated plus maze (EPM) and the light-dark tests (LDT), locomotor and grooming activities were assessed in the open-field test (OFT).
Results: Cholecalciferol in high doses alone or in combination with 17β-E2-induced anxiolytic-like effects in OVX and OVX rats treated with 17β-E2 as evidenced in the EPM and LDT tests, and increased grooming activity in the OFT test. We found that DA and 5-HT levels increased while 5-HT turnover in the hippocampus decreased in these groups of OVX rats.
Conclusion: Our results indicate that cholecalciferol in high doses has a marked anxiolytic-like effect due to an increase in the monoamines levels in the experimental rat model of estrogen deficiency.
1. Somers JM, Goldner EM, Waraich P, et al. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006;51:100-13.
2. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust 2009;190:S54-S60.
3. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162-71.
4. Martin-Merino E, Ruigomez A, Wallander MA, et al. Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract 2010;27:9-16.
5. Kronke K, Spitzer RL, Williams JB. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25.
6. Sherwin BB. Estrogen and cognitive aging in women. Trends Pharmacol Sci 2006;138:1021-6.
7. Markou A, Duka T, Prelevic GM. Estrogens and brain function. Hormones 2009;4:9-17.
8. Harsh V, Meltzer-Brody S, Rubinow DR, et al. Reproductive aging, sex steroids, and mood disorders. Harv Rev Psychiatry 2009;17:87-102.
9. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006;31:1097-111.
10. Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review. Menopause 2015;22:564-78.
11. Castanho TC, Moreira PS, Portugal-Nunes C, et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol 2014;103:158-66.
12. Silva I, Naftolin F. Brain health and cognitive and mood disorders in ageing women. Best Pract Res Clin Obstet Gynaecol 2013;27:661-72.
13. Marshall KM. Introduction to the interaction between gonadal steroids and the central nervous system. Curr Top Behav Neurosci 2011;8:1-13.
14. Fedotova J. Anxiolytic-like effect of quinpirole in combination with a low dose of 17β-estradiol in ovariectomized rats. Acta Physiol Hung 2013;100:211-23.
15. Fedotova J, Hartmann G, Lenard G, et al. Effects of 5-HT1A receptor agonist and antagonist on anxiety in intact and ovariectomized female rats. Acta Physiol Hung 2004;91:175-84.
16. DeLuca GC, Kimball SM, Kolasinski J, et al. Review: The role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 2013; 39:458-84.
17. Groves NJ, McGrath JJ, Burne TH. Vitamin D as a neurosteroid affecting the developing and adult brain. Annu Rev Nutr 2014;34:117-41.
18. Kesby JP, Eyles DW, Burne TH, et al. The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol 2011;347:121-7.
19. Stewart A, Wong K, Cachat J, et al. Neurosteroid vitamin D system as a nontraditional drug target in neuropsychopharmacology. Behav Pharmacol 2010;21:420-6.
20. Wrzosek M, Łukaszkiewicz J, Wrzosek M, et al. Vitamin D and the central nervous system. Pharmacol Rep 2013;65:271-8.
21. Eyles DW, Liu PY, Josh P, et al. Intracellular distribution of the vitamin D receptor in the brain: comparison with classic target tissues and redistribution with development. Neuroscience 2014;268:1-9.
22. Kiraly SJ, Kiraly MA, Hawe RD, et al. Vitamin D as neuroactive substance: review. Scientific World-Journal 2006;6:125-39.
23. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-5.
24. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a neuroimmunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009;34 Suppl 1:S265-77.
25. Green S. Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci 1991;14:101-104.
26. Komaki A, Abdollahzadeh F, Sarihi A, et al. Interaction between antagonist of cannabinoid receptor and antagonist of adrenergic receptor on anxiety in male rat. Basic Clin Neurosci 2014;5:218-24.
27. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified? Eur Neuropsychopharmacol 1999;9:399-405.
28. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol Biochem Behav 1986;24:526-30.
29. Sanchez B, Relova JL, Gallego R, et al. 1,25-dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res 2009;87:723-32.
30. Stanzione P, Calabresi P, Mercuri N, et al. Dopamine modulates CA1 hippocampal neurones by elevating the threshold for spike generation: an in vitro study. Neuroscience 1984;13:1105-16.
31. Pick U, Haramaki N, Constantinescu A, et al. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for α-lipoic acid enantiomers. Biochem Biophys Res Commun 1995;206:724-30.
32. Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 2003;28:830-38.
33. Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Interaction between estrogens and antidepressants in the forced swimming test in rats. Psychopharmacology 2004;173:139-45.
34. Idrus NM, Happer JP, Thomas JD. Cholecalciferol attenuates perseverative behavior associated with developmental alcohol exposure in rats in a dose-dependent manner. J Steroid Biochem Mol Biol 2013;136:146-9.
35. Mora S, Díaz-Véliz G, Millán R, et al. Anxiolytic and antidepressant-like effects of the hydroalcoholic extract from Aloysia polystachya in rats. Pharmacol Biochem Behav 2005;82:373-8.
36. Pellow S, Chopin P, File SE, et al. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149-67.
37. Menzaghi F, Howard RL, Heinrichs SC, et al. Characterization of a novel and potent corticotrophin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994;269:564-72.
38. Edinger KL, Frye CA. Sexual experience of male rats influences anxiety-like behavior and androgen levels. Physiol Behav 2007;92:443-53.
39. Pan HZ, Chen HH. Hyperalgesia, low-anxiety, and impairment of avoidance learning in neonatal caffeine-treated rats. Psychopharmacology (Berl) 2006;191:119-25.
40. Walf AA, Frye CA. ERbeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. Neuropsychopharmacology 2005;30:1598-1609.
41. Fedotova J, Soultanov V, Nikitina T, et al. Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia. Phytomedicine 2012;19:451-6.
42. Cavalheiro EA, Fernandes MJ, Turski L, et al. Spontaneous recurrent seizures in rats: amino acid and monoamine determination in the hippocampus. Epilepsia 1994;35:1-11.
43. Donzanti BA, Yamamoto BK. An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. Life Sci 1988;43:913-22.
44. Gomes PB, Feitosa ML, Silva MI, et al. Anxiolytic like effect of the monoterpene 1,4 cineole in mice. Pharmacol Biochem Behav 2010;96:287-93.
45. Jiang P, Zhang WY, Li HD, et al. Repeated haloperidol administration has no effect on vitamin D signaling but increase retinoid X receptors and Nur77 expression in rat prefrontal cortex. Cell Mol Neurobiol 2013;33:309-12.
46. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci USA 2001;98:676-82.
47. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17.
48. Kahn R, Van Praag H, Wtzler S, et al. Serotonin and anxiety revisited. Biol Phychiatry 1988;23:189-208.
49. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-8.
50. Halasy K, Miettinen R, Szabat E, et al. GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur J Neurosci 1992;4:144-53.
51. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 2008;5:342-345.
52. Freitas RM. The evaluation of effects of lipoic acid on the lipid peroxidation, nitrite formation and antioxidant enzymes in the hippocampus of rats after pilocarpine-induced seizures. Neurosci Lett 2009;455:140-4.
53. Smith AR, Shenvi SV, Widlansky M, et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004;11:1135-46.
54. Chaudhuri A. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses 2005;64:608-18.
55. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2005;132:1146-60.
56. De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689-96.
57. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB J 2014;28:2398-413.
58. Puchacz E, Stumpf WE, Stachowiak EK, et al. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res 1996;36:193-6.
59. Groves NJ, Kesby JP, Eyles DW, et al. Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice. Behav Brain Res 2013;241:120-31.
60. Byrne JH, Voogt M, Turner KM, et al. The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. PLoS One 2013;8:e71593.
61. Ishikawa K, Ott T, McGaugh JL. Evidence for dopamine as a transmitter in dorsal hippocampus. Brain Res 1982;232:222-6.